Diagnostic Center | October 30, 2023
SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
‘Sanjeevani’ aims to raise awareness and encourage conversations around the silent cancer epidemic
The state-of-the-art digital PETCT imaging system, highlights a significant advancement in the fight against cancer and detects other lesions offering patient centric services
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Subscribe To Our Newsletter & Stay Updated
